Report cover image

Global Therapeutic Proteins and Oral Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 191 Pages
SKU # APRC20360001

Description

Summary

According to APO Research, the global Therapeutic Proteins and Oral Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Therapeutic Proteins and Oral Vaccines market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Therapeutic Proteins and Oral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Therapeutic Proteins and Oral Vaccines market include Abbott, Sanofi, Merck, Roche, Pfizer, Amgen, TransAlgae, Serum Institute of India and Novo Nordisk, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Therapeutic Proteins and Oral Vaccines, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Therapeutic Proteins and Oral Vaccines, also provides the value of main regions and countries. Of the upcoming market potential for Therapeutic Proteins and Oral Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Proteins and Oral Vaccines revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Proteins and Oral Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Therapeutic Proteins and Oral Vaccines company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Therapeutic Proteins and Oral Vaccines Segment by Company

Abbott
Sanofi
Merck
Roche
Pfizer
Amgen
TransAlgae
Serum Institute of India
Novo Nordisk
MigVax
Lumen Bioscience
Johnson and Johnson
Emergent Biosolutions
Eli Lilly and Company
Biogen
Therapeutic Proteins and Oral Vaccines Segment by Type

Therapeutic Proteins
Oral Vaccines
Therapeutic Proteins and Oral Vaccines Segment by Application

Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Therapeutic Proteins and Oral Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Therapeutic Proteins and Oral Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Therapeutic Proteins and Oral Vaccines key companies, revenue, market share, and recent developments.
3. To split the Therapeutic Proteins and Oral Vaccines breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Therapeutic Proteins and Oral Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Proteins and Oral Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Proteins and Oral Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins and Oral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins and Oral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins and Oral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Proteins and Oral Vaccines industry.
Chapter 3: Detailed analysis of Therapeutic Proteins and Oral Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Therapeutic Proteins and Oral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Therapeutic Proteins and Oral Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Therapeutic Proteins and Oral Vaccines Market Size, 2020 VS 2024 VS 2031
1.3 Global Therapeutic Proteins and Oral Vaccines Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Therapeutic Proteins and Oral Vaccines Market Dynamics
2.1 Therapeutic Proteins and Oral Vaccines Industry Trends
2.2 Therapeutic Proteins and Oral Vaccines Industry Drivers
2.3 Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges
2.4 Therapeutic Proteins and Oral Vaccines Industry Restraints
3 Therapeutic Proteins and Oral Vaccines Market by Company
3.1 Global Therapeutic Proteins and Oral Vaccines Company Revenue Ranking in 2024
3.2 Global Therapeutic Proteins and Oral Vaccines Revenue by Company (2020-2025)
3.3 Global Therapeutic Proteins and Oral Vaccines Company Ranking (2023-2025)
3.4 Global Therapeutic Proteins and Oral Vaccines Company Manufacturing Base and Headquarters
3.5 Global Therapeutic Proteins and Oral Vaccines Company Product Type and Application
3.6 Global Therapeutic Proteins and Oral Vaccines Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Therapeutic Proteins and Oral Vaccines Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Therapeutic Proteins and Oral Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Therapeutic Proteins and Oral Vaccines Market by Type
4.1 Therapeutic Proteins and Oral Vaccines Type Introduction
4.1.1 Therapeutic Proteins
4.1.2 Oral Vaccines
4.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type
4.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2020-2031)
4.2.3 Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Type (2020-2031)
5 Therapeutic Proteins and Oral Vaccines Market by Application
5.1 Therapeutic Proteins and Oral Vaccines Application Introduction
5.1.1 Retail Pharmacies
5.1.2 Online Pharmacies
5.1.3 Hospital Pharmacies
5.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application
5.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2020-2031)
5.2.3 Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Application (2020-2031)
6 Therapeutic Proteins and Oral Vaccines Regional Value Analysis
6.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2020-2031)
6.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region: 2020-2025
6.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Therapeutic Proteins and Oral Vaccines Sales Value (2020-2031)
6.3.2 North America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Therapeutic Proteins and Oral Vaccines Sales Value (2020-2031)
6.4.2 Europe Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value (2020-2031)
6.5.2 Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Therapeutic Proteins and Oral Vaccines Sales Value (2020-2031)
6.6.2 South America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value (2020-2031)
6.7.2 Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2024 VS 2031
7 Therapeutic Proteins and Oral Vaccines Country-level Value Analysis
7.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2020-2031)
7.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2020-2025)
7.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.3.2 USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.4.2 Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.7.2 France Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.7.3 France Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 China Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 China Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 India Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 India Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Abbott
8.1.1 Abbott Comapny Information
8.1.2 Abbott Business Overview
8.1.3 Abbott Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.1.4 Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio
8.1.5 Abbott Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Merck
8.3.1 Merck Comapny Information
8.3.2 Merck Business Overview
8.3.3 Merck Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.3.4 Merck Therapeutic Proteins and Oral Vaccines Product Portfolio
8.3.5 Merck Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.4.4 Roche Therapeutic Proteins and Oral Vaccines Product Portfolio
8.4.5 Roche Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 Amgen
8.6.1 Amgen Comapny Information
8.6.2 Amgen Business Overview
8.6.3 Amgen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.6.4 Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio
8.6.5 Amgen Recent Developments
8.7 TransAlgae
8.7.1 TransAlgae Comapny Information
8.7.2 TransAlgae Business Overview
8.7.3 TransAlgae Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.7.4 TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio
8.7.5 TransAlgae Recent Developments
8.8 Serum Institute of India
8.8.1 Serum Institute of India Comapny Information
8.8.2 Serum Institute of India Business Overview
8.8.3 Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.8.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio
8.8.5 Serum Institute of India Recent Developments
8.9 Novo Nordisk
8.9.1 Novo Nordisk Comapny Information
8.9.2 Novo Nordisk Business Overview
8.9.3 Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.9.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio
8.9.5 Novo Nordisk Recent Developments
8.10 MigVax
8.10.1 MigVax Comapny Information
8.10.2 MigVax Business Overview
8.10.3 MigVax Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.10.4 MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio
8.10.5 MigVax Recent Developments
8.11 Lumen Bioscience
8.11.1 Lumen Bioscience Comapny Information
8.11.2 Lumen Bioscience Business Overview
8.11.3 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.11.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio
8.11.5 Lumen Bioscience Recent Developments
8.12 Johnson and Johnson
8.12.1 Johnson and Johnson Comapny Information
8.12.2 Johnson and Johnson Business Overview
8.12.3 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.12.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio
8.12.5 Johnson and Johnson Recent Developments
8.13 Emergent Biosolutions
8.13.1 Emergent Biosolutions Comapny Information
8.13.2 Emergent Biosolutions Business Overview
8.13.3 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.13.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio
8.13.5 Emergent Biosolutions Recent Developments
8.14 Eli Lilly and Company
8.14.1 Eli Lilly and Company Comapny Information
8.14.2 Eli Lilly and Company Business Overview
8.14.3 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.14.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio
8.14.5 Eli Lilly and Company Recent Developments
8.15 Biogen
8.15.1 Biogen Comapny Information
8.15.2 Biogen Business Overview
8.15.3 Biogen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2020-2025)
8.15.4 Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio
8.15.5 Biogen Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.